Neurofilament as a biomarker of neurodegeneration in childhood Langerhans cell histiocytosis: A feasibility study on 273 patients
- 5 April 2026
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2113-2123
Abstract
Summary: Neurodegeneration (ND) is a severe complication of Langerhans cell histiocytosis (LCH), often leading to progressive neurological decline. We evaluated the usefulness of using plasma and cerebrospinal fluid neurofilament light chain (p‐ and CSF‐NFL) levels as biomarkers to identify and monitor ND‐LCH. NFL levels were measured using the single‐molecule array for a subset of patients from the French National LCH Registry. NFL levels in 692 plasma and 115 CSF samples from 273 registry‐enrolled children were analysed. Based on 84 paired plasma and CSF samples from 67 patients, p‐ and CSF‐NFL levels were strongly correlated ( p < 0.0001). The areas under the receiver operating characteristics curves for ND‐LCH were 72% (95% confidence interval [CI], 64%–78%) for p‐NFL and 94% (95% CI, 88%–98%) for CSF‐NFL. The highest p‐NFL (13.7 vs. 7.2 pg/mL; z ‐score 2.3 vs. 0.6) and CSF‐NFL (436.9 vs. 65.2 pg/mL) levels were significantly higher for ND‐LCH than in no‐ND‐LCH patients, respectively ( p < 0.0001). Plasma NFL levels were not elevated at LCH diagnosis. At LCH diagnosis, p‐NFL was not predictive of ND, but it may serve as a minimally invasive screening tool for ND in LCH, although optimal timing remains to be determined.Keywords
Funding Information
- Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent
- Les 111 des Arts
This publication has 37 references indexed in Scilit:
- Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNAInternational Journal of Hematology, 2021
- Blood neurofilament light: a critical review of its application to neurologic diseaseAnnals of Clinical and Translational Neurology, 2020
- CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH‐associated neurodegeneration and mass lesionsCancer, 2018
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnnals of Neurology, 2017
- The cognitive spectrum in neurodegenerative Langerhans cell histiocytosisJournal of Neurology, 2014
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosisPediatric Blood & Cancer, 2009
- Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosisEuropean Journal of Cancer, 2006
- MRI features of neurodegenerative Langerhans cell histiocytosisEuropean Radiology, 2006
- Risk factors for diabetes insipidus in langerhans cell histiocytosisPediatric Blood & Cancer, 2005